TY - JOUR
T1 - Epidemic of parvovirus B19 and disease severity in pregnant people, Denmark, January to March 2024
AU - Nordholm, Anne Christine
AU - Møller, Frederik Trier
AU - Ravn, Signe Fischer
AU - Sørensen, Lotte Flink
AU - Moltke-Prehn, Anja
AU - Mollerup, Jacob Elskær
AU - Funk, Tjede
AU - Sperling, Lene
AU - Jeyaratnam, Ulisa
AU - Franck, Kristina Træholt
AU - Hjort-Pedersen, Karina
AU - Kamper, Christina Hjørnet
AU - Nielsen, Rikke Thoft
AU - Jokelainen, Pikka
AU - Wessman, Maria
PY - 2024/6/13
Y1 - 2024/6/13
N2 - We report an epidemic of parvovirus B19 infections in Denmark during the first quarter of 2024, with a peak incidence 3.5 times higher than during the most recent epidemic in 2017. In total, 20.1% (130/648) of laboratory-confirmed cases were pregnant. Severe adverse outcomes were observed among 12.3% (16/130) of pregnant people and included foetal anaemia, foetal hydrops and miscarriage. Parvovirus B19 infection is not systematically monitored, but a national laboratory-based surveillance system is currently being established in Denmark. Parvovirus B19 infection, a common childhood infection, is an important concern for pregnant people in Europe, where up to 40% may be susceptible to the infection [1,2]. Parvovirus B19 usually causes mild disease, but it poses a risk to seronegative pregnant people, potentially resulting in severe outcomes such as anaemia, hydrops fetalis, foetal death or miscarriage [1,2]. In March 2024, clinicians in Denmark notified an increased number of hospitalisations and complications in pregnant people with parvovirus infection to the national public health institute, Statens Serum Institut (SSI), and a register-based study was initiated to investigate epidemiological trends and disease severity.
AB - We report an epidemic of parvovirus B19 infections in Denmark during the first quarter of 2024, with a peak incidence 3.5 times higher than during the most recent epidemic in 2017. In total, 20.1% (130/648) of laboratory-confirmed cases were pregnant. Severe adverse outcomes were observed among 12.3% (16/130) of pregnant people and included foetal anaemia, foetal hydrops and miscarriage. Parvovirus B19 infection is not systematically monitored, but a national laboratory-based surveillance system is currently being established in Denmark. Parvovirus B19 infection, a common childhood infection, is an important concern for pregnant people in Europe, where up to 40% may be susceptible to the infection [1,2]. Parvovirus B19 usually causes mild disease, but it poses a risk to seronegative pregnant people, potentially resulting in severe outcomes such as anaemia, hydrops fetalis, foetal death or miscarriage [1,2]. In March 2024, clinicians in Denmark notified an increased number of hospitalisations and complications in pregnant people with parvovirus infection to the national public health institute, Statens Serum Institut (SSI), and a register-based study was initiated to investigate epidemiological trends and disease severity.
KW - Abortion, Spontaneous/epidemiology
KW - Adolescent
KW - Adult
KW - Denmark/epidemiology
KW - Epidemics
KW - Erythema Infectiosum/epidemiology
KW - Female
KW - Humans
KW - Hydrops Fetalis/epidemiology
KW - Incidence
KW - Parvoviridae Infections/epidemiology
KW - Parvovirus B19, Human/isolation & purification
KW - Population Surveillance
KW - Pregnancy
KW - Pregnancy Complications, Infectious/epidemiology
KW - Severity of Illness Index
KW - Young Adult
U2 - 10.2807/1560-7917.ES.2024.29.24.2400299
DO - 10.2807/1560-7917.ES.2024.29.24.2400299
M3 - Journal article
C2 - 38873795
AN - SCOPUS:85196137817
SN - 1025-496X
VL - 29
JO - Eurosurveillance
JF - Eurosurveillance
IS - 24
M1 - 2400299
ER -